论文信息 - First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study - 字舞流文

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

E. González-Barca | I. Flinn | S. Opat | J. Pagel | C. Tam | A. Tedeschi | E. Szafer-Glusman | W. Wierda | J. Dean | T. Siddiqi | P. Ghia | Cathy Zhou | R. Jacobs | B. Kuss | J. Allan | J. Barrientos | T. Kipps | X. Badoux | J. Ninomoto